Medical device company MirRus raised $65 million in a round of funding for its Rhenium-based spine devices and heart disease treatment development, the company said July 27.
"This funding will allow us to meet the overwhelming demand from spine surgeons across the country for our highly differentiated products and procedural solutions using the MoRe® superalloy and continue our planned expansion into other important areas, including structural heart disease," MiRus founder and CEO Jay Yadav, MD, said in a news release.
The Marietta, Ga.-based company touts the performance of its Rhenium alloy products, known as MoRe, compared to traditional alloy medical devices, such that it promises "if the MoRe® rod ever fails, leading to revision surgery, MiRus will pay for the cost of all revision implants," the release said.
Venture capital firm Mammoth Scientific and practices supporting MiRus led the funding round, MiRus said.